Format

Send to

Choose Destination
JAMA Oncol. 2016 Aug 1;2(8):1094-6. doi: 10.1001/jamaoncol.2016.1056.

Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma.

Author information

1
Dana-Farber Cancer Institute, Boston, Massachusetts.
2
Fox Chase Cancer Center, Philadelphia, Pennsylvania.
3
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.
4
Dana-Farber Cancer Institute, Boston, Massachusetts3Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge.
5
Memorial Sloan Kettering Cancer Center, New York, New York.
PMID:
27310333
PMCID:
PMC5515075
DOI:
10.1001/jamaoncol.2016.1056
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center